A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment.
暂无分享,去创建一个
[1] H J Clewell,et al. Physiologically-Based Pharmacokinetic Modeling and Bioactivation of Xenobiotics , 1994, Toxicology and industrial health.
[2] H J Clewell,et al. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. , 1996, Toxicology.
[3] M E Andersen,et al. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. , 1989, Toxicology and applied pharmacology.
[4] M E Andersen,et al. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.
[5] F. A. Smith,et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.
[6] H J Clewell,et al. Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. , 2000, Environmental health perspectives.
[7] M E Andersen,et al. Biologically based pharmacodynamic models: tools for toxicological research and risk assessment. , 1991, Annual review of pharmacology and toxicology.
[8] H J Clewell,et al. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. , 1996, Toxicology.
[9] H J Clewell,et al. Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.
[10] R B Conolly,et al. Computer simulation of cell growth governed by stochastic processes: application to clonal growth cancer models. , 1994, Toxicology and applied pharmacology.
[11] H J Clewell,et al. The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. , 1995, Toxicology letters.
[12] D W Potter,et al. A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. , 1992, Toxicology and applied pharmacology.
[13] H J Clewell,et al. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.
[14] P J Bushnell,et al. Concentration-time relationships for the effects of inhaled trichloroethylene on signal detection behavior in rats. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[15] M E Andersen,et al. Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.
[16] M E Andersen,et al. Saturable metabolism and its relationship to toxicity. , 1981, Critical reviews in toxicology.
[17] A. Monro,et al. What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? , 1992, Toxicology and applied pharmacology.
[18] Timothy R. Gerrity,et al. Principles of route-to-route extrapolation for risk assessment : proceedings of the Workshops on Principles of Route-to-Route Extrapolation for Risk Assessment held March 19-21, 1990, in Hilton Head, South Carolina and July 10-11, 1990, in Durham, North Carolina , 1990 .
[19] H J Clewell,et al. Biologically motivated models for chemical risk assessment. , 1989, Health physics.
[20] John F Young Bernard A Schwetz Calv. SYMPOSIUM ON PHARMACOKINETICS PHARMACODYNAMICS IN THE DEVELOPING SYSTEM AND IMPACT ON RISK ASSESSMENT EXECUTIVE SUMMARY , 1996 .
[21] Annie M. Jarabek,et al. CONSIDERATION OF TEMPORAL TOXICITY CHALLENGES CURRENT DEFAULT ASSUMPTIONS , 1995 .
[22] H J Clewell,et al. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. , 2000, Environmental health perspectives.
[23] M. Andersen,et al. Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.
[24] Dedrick Rl,et al. Pharmacokinetic and pharmacodynamic considerations for chronic hemodialysis. , 1975, Kidney international. Supplement.
[25] Kenny S. Crump,et al. Calculation of Benchmark Doses from Continuous Data , 1995 .
[26] H J Clewell,et al. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment. , 1997, Journal of toxicology and environmental health.
[27] H J Clewell. Incorporating biological information in quantitative risk assessment: an example with methylene chloride. , 1995, Toxicology.
[28] Hugh A. Barton,et al. Harmonization: Developing Consistent Guidelines for Applying Mode of Action and Dosimetry Information to Cancer and Noncancer Risk Assessment , 1998 .
[29] Vera Thomas. Biological-Mathematical Modeling of Chronic Toxicity. , 1981 .
[30] R L Dedrick. Pharmacokinetic and pharmacodynamic considerations for chronic hemodialysis. , 1975, Kidney international. Supplement.
[31] K S Crump,et al. An improved procedure for low-dose carcinogenic risk assessment from animal data. , 1984, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[32] J. N. Blancato,et al. Update to the health assessment document and addendum for dichloromethane (methylene chloride): pharmacokinetics, mechanism of action, and epidemiology. External review draft , 1987 .
[33] J M Collins,et al. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. , 1990, Regulatory toxicology and pharmacology : RTP.
[34] H J Clewell,et al. Risk assessment of chemical mixtures: biologic and toxicologic issues. , 1993, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[35] C B Frederick,et al. Limiting the uncertainty in risk assessment by the development of physiologically based pharmacokinetic and pharmacodynamic models. , 1993, Toxicology letters.
[36] V A Benignus,et al. A dosimetric analysis of behavioral effects of acute toluene exposure in rats and humans. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.
[37] D J Paustenbach,et al. Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model. , 1987, American Industrial Hygiene Association journal.
[38] James D. Crapo,et al. Extrapolation of Dosimetric Relationships for Inhaled Particles and Gases , 1989 .
[39] R A Corley,et al. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. , 1994, Toxicology and applied pharmacology.
[40] R. Hertzberg,et al. A new method for determining allowable daily intakes. , 1986, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[41] Fritz Haber,et al. Zur Geschichte des Gaskrieges , 1924 .
[42] H. J. Clewell,et al. Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiological study , 1995 .
[43] Ellen J. O'Flaherty,et al. Interspecies Conversion of Kinetically Equivalent Doses1 , 1989 .
[44] H J Clewell,et al. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.